Rubric Capital and Velan Capital Reach Agreement with Heron Therapeutics for Board Representation and Corporate Governance Improvements
Olshan clients Rubric Capital and Velan Capital reached an agreement with Heron Therapeutics, according to which three new independent directors were appointed to Heron’s board – including Adam Morgan of Velan Capital – and two incumbent directors departed the board. The company also agreed to separate the Chairman and CEO roles effective immediately following the company’s upcoming annual meeting.